Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy
| Errataetall: |
CommentOn: J Clin Oncol. 2021 Aug 1;39(22):2423-2425. - PMID 34111942 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 40(2022), 1 vom: 01. Jan., Seite 106-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garfall, Alfred [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.02.2022 Date Revised 11.02.2022 published: Print-Electronic CommentOn: J Clin Oncol. 2021 Aug 1;39(22):2423-2425. - PMID 34111942 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.21.01754 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331934256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331934256 | ||
| 003 | DE-627 | ||
| 005 | 20231225214550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.21.01754 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331934256 | ||
| 035 | |a (NLM)34652957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garfall, Alfred |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2022 | ||
| 500 | |a Date Revised 11.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Clin Oncol. 2021 Aug 1;39(22):2423-2425. - PMID 34111942 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Cohen, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Stadtmauer, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Susanibar-Adaniya, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vogl, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Waxman, Adam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 40(2022), 1 vom: 01. Jan., Seite 106-107 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:106-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.21.01754 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 1 |b 01 |c 01 |h 106-107 | ||